Validating Disease Associations of Drug-Metabolizing Enzymes through Genome-Wide Association Study Data Analysis

Area of Science:

• Pharmacogenomics
• Metabolomics
• Human Genetics

Background:

• Phase I and II drug-metabolizing enzymes (DMEs) are vital for processing endogenous and exogenous compounds.
• In vitro and animal studies suggest genetic mutations in DMEs increase cancer risk.
• Human in vivo evidence linking DME genetic variations to cancer remains limited.

Purpose of the Study:

• To identify diseases genetically associated with drug-metabolizing enzymes using genome-wide association studies (GWASs).
• To focus on the UDP-glucuronosyltransferase (UGT) enzyme family.

Main Methods:

• Analysis of a genome-wide association studies (GWASs) database.
• Comparison of genetic data between large groups of individuals.
• Focus on identifying associations with UDP-glucuronosyltransferases (UGTs).

Main Results:

• Confirmed a strong association between the UGT1 gene and hyperbilirubinemia.
• Identified over ten studies linking the UGT1 gene to elevated low-density lipoprotein (LDL) cholesterol.
• Found UGT2B7 associated with testosterone, total cholesterol, and vitamin D levels.

Conclusions:

• GWAS data did not show a genetic link between UGT1/UGT2 enzymes and cancer, despite their in vitro carcinogen-metabolizing capabilities.
• One study linked UGT2B4 to ovarian cancer, warranting further investigation.
• Further research is needed to reconcile in vitro, animal, and human in vivo findings.